Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-42.32%||Sales Growth - Q/Q||-57%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.86%||ROE||6.59%||ROI||4.26%|
|Current Ratio||5.05||Quick Ratio||4.03||Long Term Debt/Equity||0.77||Debt Ratio||0.15|
|Gross Margin||74.31%||Operating Margin||12%||Net Profit Margin||7.71%||Dividend Payout Ratio|
|Cash From Financing Activities||11 M||Cash From Investing Activities||-9.08 M||Cash From Operating Activities||-65.87 M||Gross Profit||44.88 M|
|Net Profit||-21.52 M||Operating Profit||-28.31 M||Total Assets||917.85 M||Total Current Assets||405.81 M|
|Total Current Liabilities||80.3 M||Total Debt||251 M||Total Liabilities||379.97 M||Total Revenue||63.63 M|
|High 52 week||73.24||Low 52 week||39.92||Last close||43.62||Last change||-0.93%|
|RSI||53.62||Average true range||1.93||Beta||0.83||Volume||333.02 K|
|Simple moving average 20 days||-0.45%||Simple moving average 50 days||-2.41%||Simple moving average 200 days||-20.53%|
|Performance Week||-2.68%||Performance Month||-0.11%||Performance Quart||-6.58%||Performance Half||-25.55%|
|Performance Year||-18.66%||Performance Year-to-date||-25.68%||Volatility daily||2.28%||Volatility weekly||5.11%|
|Volatility monthly||10.46%||Volatility yearly||36.25%||Relative Volume||180.22%||Average Volume||378.21 K|
|New High||New Low|
2019-11-13 09:30:02 | EBS or ILMN: Which Is the Better Value Stock Right Now?
2019-11-07 13:22:48 | Edited Transcript of EBS earnings conference call or presentation 6-Nov-19 10:00pm GMT
2019-11-07 11:20:04 | Emergent EBS Beat Earnings in Q3, Vaccines Drive Sales
2019-11-06 19:05:12 | Emergent Biosolutions EBS Q3 Earnings and Revenues Beat Estimates
2019-10-30 10:34:02 | Emergent Biosolutions EBS Earnings Expected to Grow: Should You Buy?
2019-10-21 11:34:06 | Here’s What Hedge Funds Think About Emergent Biosolutions Inc EBS
2019-10-21 06:30:05 | Emergent BioSolutions to Host 2019 Analyst & Investor Day
2019-10-11 12:53:04 | Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
2019-10-10 09:34:05 | New Stocks on the Argus Focus List
2019-10-08 10:31:02 | Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
2019-09-26 14:46:30 | Emergent lands $20M contract to develop chemical weapon antidote
2019-09-26 09:27:42 | Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
2019-09-19 11:25:12 | Emergent BioSolutions Inc. NYSE:EBS Insiders Have Been Selling
2019-09-04 12:25:19 | Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement
2019-09-04 10:02:02 | Company News For Sep 4, 2019
2019-09-03 13:28:47 | Emergent lands federal contract for smallpox vaccine potentially worth more than $2B
2019-09-03 12:55:00 | Here's How Emergent BioSolutions Procured a Higher Price Today
2019-08-31 09:31:01 | Emergent Biosolutions EBS Down 0.9% Since Last Earnings Report: Can It Rebound?
2019-08-28 14:28:06 | Emergent's Vaccine Portfolio Aids Growth Amid Competition
2019-08-14 16:15:00 | Emergent BioSolutions to Participate in Series of Investor Conferences
2019-08-14 07:48:14 | Here's Why Emergent BioSolutions NYSE:EBS Has A Meaningful Debt Burden
2019-08-06 10:14:00 | Emergent BioSolutions Looks to the Second Half for Growth
2019-08-06 06:26:51 | Emergent BioSolutions Inc EBS Q2 2019 Earnings Call Transcript
2019-08-02 10:52:02 | Emergent EBS Earnings Miss in Q2, Revenues Beat Estimates
2019-08-02 03:39:32 | Edited Transcript of EBS earnings conference call or presentation 1-Aug-19 9:00pm GMT
2019-08-01 20:25:12 | Emergent Biosolutions EBS Q2 Earnings Lag Estimates
2019-07-30 16:42:29 | Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
2019-07-25 10:33:02 | Earnings Preview: Emergent Biosolutions EBS Q2 Earnings Expected to Decline
2019-07-09 06:08:15 | Here's What Emergent BioSolutions Inc.'s NYSE:EBS P/E Is Telling Us
2019-06-28 18:12:19 | Here’s What Hedge Funds Think About Emergent Biosolutions Inc EBS
2019-06-18 08:05:15 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-15 08:07:01 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-14 14:27:22 | Before You Buy Emergent BioSolutions Inc. NYSE:EBS, Consider Its Volatility
2019-06-10 08:07:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-05 13:20:58 | Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic
2019-06-05 09:52:00 | Emergent BioSolutions Looks Like It Will Get a Shot in the Arm
2019-06-04 18:58:00 | Don't Get Complacent: Cramer's 'Mad Money' Recap Tuesday 6/4/19
2019-06-04 11:52:03 | Emergent EBS Wins HHS Contract to Supply VIGIV Product
2019-06-04 08:06:06 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-06-03 14:53:59 | What Emergent’s latest $535M contract means for national ‘smallpox franchise’